Opendata, web and dolomites

TRIC-TB SIGNED

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRIC-TB project word cloud

Explore the words cloud of the TRIC-TB project. It provides you a very rough idea of what is the project "TRIC-TB" about.

clinical    universal    ethionamide    bvl    significantly    rates    time    active    combinations    outcomes    extensive    starting    glaxosmithkline    vivo    percent    benefit    vital    human    patient    collaborators    exploration    boost    xdr    mtb    restore    scientific    university    cure    synergistic    compounds    mdr    list    million    compound    treatment    70    proprietary    status    medicines    world    therapeutic    transcriptional    once    gsk098    multidrug    independently    suffers    pd    optimization    480    class    2016    bioversys    relapse    extensively    clinically    gsk038    regimen    tuberculosis    therapy    sensitive    killed    people    drug    action    dosing    vitro    overcoming    lille    mechanism    again    first    2nd    ind    eth    communities    proven    pk    levels    placement    modulators    kill    strains    infection       infectious    mycobacterium    reported    resistant    ultimately    acting    resistance    leads    line    mortality    disease    previously    tb    doses    safety    lower    boosted   

Project "TRIC-TB" data sheet

The following table provides information about the project.

Coordinator
BIOVERSYS AG 

Organization address
address: HOCHBERGERSTRASSE 60 C TECHNOLOGIEPARK BASEL
city: BASEL
postcode: 4057
website: www.bioversys.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 8˙373˙250 €
 EC max contribution 6˙926˙375 € (83%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-16-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOVERSYS AG CH (BASEL) coordinator 6˙926˙375.00
2    GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL ES (TRES CANTOS) participant 0.00

Map

 Project objective

Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year. In 2016, 480’000 of TB cases were multidrug-resistant (MDR-TB) and 9% percent of those cases are extensively drug-resistant (XDR), with mortality rates as high as 70%. Ethionamide (ETH) is a vital part of the WHO essential medicines list of 2nd-line TB therapy for MDR-TB, however, ETH suffers from significant levels of resistance and side effects at current dosing levels. BVL-GSK038 and BVL-GSK098 are proprietary to BioVersys/GlaxoSmithKline and have been developed through an extensive Lead Optimization program with collaborators from Lille University. Low doses of both compounds fully restore and “boost” the activity of ETH to rapidly kill Mycobacterium tuberculosis (Mtb) including MDR strains at significantly lower doses of ETH than previously reported, thus making MDR-TB sensitive to ETH once again. Through a comprehensive IND enabling package including in vitro and in vivo assessment of ETH with BVL-GSK038 and BVL-GSK098, including PK/PD, resistance development, safety, mechanism of action and synergistic studies with different drug compound combinations and then first in human clinical studies the consortium aims to:

i) Define the future placement of a boosted ETH (ETH BVL-GSK038 or BVL-GSK098) in a universal TB treatment regimen, including overcoming MDR-TB with improved safety, time to cure and relapse rates;

Ultimately, we expect to identify a new and clinically proven TB regimen that leads to better patient outcomes independently of the starting resistance status of the TB infection. The TB and wider scientific communities will benefit from an improved understanding of ETH and the exploration of a novel class of therapeutic compounds acting on transcriptional modulators (BVL-GSK038 and BVL-GSK098).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIC-TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRIC-TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More